RetinalGenix appoints Vinay Mehindru, MD, MBA to board of directors

RetinalGenix Technologies Inc.

Vinay Mehindru, age 55, appointed director effective July 25, 2022.
He has over 25 years of healthcare experience; currently CEO of Exemplary Health.
Previously President of AdventHealth's clinically integrated networks (2014-2019) and CMO.
No family relationships or material interests with company directors or officers.
Appointment fills board seat; no departure of existing directors.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Vinay Mehindru

director

RTGN · RetinalGenix Technologies Inc.

Effective: 2022-07-25
Filed: July 28, 2022, 7:59 PM ET

On July 25, 2022, the Board of Directors (the “Board”) of RetinalGenix Inc. (the ‘Company”) appointed Vinay Mehindru, MD, MBA to serve as a director of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Vinay Mehindru was appointed as director at RetinalGenix Technologies Inc..

Action: appointed
Role: director

Exact text from the filing

On July 25, 2022, the Board of Directors (the “Board”) of RetinalGenix Inc. (the ‘Company”) appointed Vinay Mehindru, MD, MBA to serve as a director of the Company.

View on SEC.gov

RetinalGenix Technologies Inc. filing history →

Source: SEC EDGAR

accession 0001493152-22-020481

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.